Why Investors Loved Moderna's Q3 Results

Keith Speights, The Motley Fool
·3-min read
Why Investors Loved Moderna's Q3 Results
Why Investors Loved Moderna's Q3 Results

Moderna's (NASDAQ: MRNA) primary focus right now is to hopefully win regulatory approvals or authorizations for coronavirus vaccine mRNA-1273 to make it to the market. Moderna reported revenue in the third quarter of $157.9 million, up a whopping 829% year over year. Perhaps the most important financial measure for Moderna was its cash position at the end of the third quarter.